On the Laplacian spectra of token graphs

We study the Laplacian spectrum of token graphs, also called symmetric powers of graphs. The k-token graph Fk(G) of a graph G is the graph whose vertices are the k-subsets of vertices from G, two of which being adjacent whenever their symmetric difference is a pair of adjacent vertices in G. In this paper, we give a relationship between the Laplacian spectra of any two token graphs of a given graph. In particular, we show that, for any integers h and k such that 1 ≤ h ≤ k ≤ n 2 , the Laplacian spectrum of Fh(G) is contained in the Laplacian spectrum of Fk(G). We also show that the doubled odd graphs and doubled Johnson graphs can be obtained as token graphs of the complete graph Kn and the star Sn = K1,n−1, respectively. Besides, we obtain a relationship between the spectra of the k-token graph of G and the k-token graph of its complement G. This generalizes to tokens graphs a wellknown property stating that the Laplacian eigenvalues of G are closely related to the Laplacian eigenvalues of G. Finally, the doubled odd graphs and doubled Johnson graphs provide two infinite families, together with some others, in which the algebraic connectivities of the original graph and its token graph coincide. Moreover, we conjecture that this is the case for any graph G and its token graph.This research of C. Dalfó and M.A. Fiol has been partially supported by AGAUR from the Catalan Government under project 017SGR1087 and by MICINN from the Spanish Government under project PGC2018-095471-B-I00. The research of C. Dalfó has also been supported by MICINN from the Spanish Government under project MTM2017-83271-R. The research of C. Huemer was supported by MICINN from the Spanish Government under project PID2019-104129GB-I00/AEI/10.13039/501100011033 and AGAUR from the Catalan Government under project 017SGR1336. F.J. Zaragoza Martínez acknowledges the support of the National Council of Science and Technology (Conacyt) and its National System of Researchers (SNI). This research has also received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 73492

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362